{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:46:38Z","timestamp":1785757598403,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"publisher","award":["1400-3-233-56148"],"award-info":[{"award-number":["1400-3-233-56148"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.msard.2025.106866","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:57:54Z","timestamp":1763693874000},"page":"106866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Determinants of change in disease-modifying drugs in patients with multiple sclerosis: A registry-based study"],"prefix":"10.1016","volume":"108","author":[{"given":"Sajjad Ghane","family":"Ezabadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Ebrahimitirtashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Khodaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh Abbasi","family":"Kasbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehdi","family":"Naghizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Aliyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Beladi-Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Massood","family":"Nabavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hossein","family":"Harirchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2310-6375","authenticated-orcid":false,"given":"Sharareh","family":"Eskandarieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106866_bib0001","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/13524585211008760","article-title":"Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review","volume":"28","author":"Allanach","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106866_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12883-021-02281-x","article-title":"Multiple sclerosis projection in Tehran, Iran using bayesian structural time series","volume":"21","author":"Amini","year":"2021","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2025.106866_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104610","article-title":"The national multiple sclerosis registry system of Iran (NMSRI): aspects and methodological dimensions","volume":"72","author":"Ayoubi","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106866_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.808370","article-title":"Adverse drug reactions with drugs used in multiple sclerosis: an analysis from the Italian pharmacovigilance database","volume":"13","author":"Barbieri","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.msard.2025.106866_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod rebound: a review of the clinical experience and management considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106866_bib0006","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1038\/s41598-021-83220-1","article-title":"Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study","volume":"11","author":"Bourdin","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106866_bib0007","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/CEOR.S163907","article-title":"Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon","author":"Chen","year":"2018","journal-title":"Clin. Outcomes Res."},{"key":"10.1016\/j.msard.2025.106866_bib0008","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106866_bib0009","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s13311-020-00869-8","article-title":"Commentary: the multiple sclerosis controversy: is it escalation or induction high efficacy?","volume":"17","author":"Coyle","year":"2020","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.msard.2025.106866_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.msard.2018.09.017","article-title":"Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: results from the global phase 4 Teri-PRO study in routine clinical practice","volume":"26","author":"Coyle","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106866_bib0011","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4274\/csmedj.galenos.2022.2022-11-11","article-title":"Expanded disability status scale (EDSS) in multiple sclerosis","volume":"2","author":"Demir","year":"2022","journal-title":"Cam Sakura Med. J"},{"key":"10.1016\/j.msard.2025.106866_bib0012","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1007\/s10072-023-07043-w","article-title":"The incidence and prevalence of crude and familial multiple sclerosis in Tehran, Iran in 2021","volume":"44","author":"Ezabadi","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106866_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103928","article-title":"Global assessment of characteristics of multiple sclerosis registries; A systematic review","volume":"63","author":"Ezabadi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106866_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103777","article-title":"Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years","volume":"61","author":"Ghadiri","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106866_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103777","article-title":"Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years","volume":"61","author":"Ghadiri","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106866_bib0016","first-page":"106","article-title":"Investigation of pregnancy tendency, reproductive characteristics, and disability in women with multiple sclerosis: A secondary data analysis of the national registry in Iran","author":"Ghane Ezabadi","year":"2024","journal-title":"Curr J Neurol"},{"key":"10.1016\/j.msard.2025.106866_bib0017","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm","volume":"31","author":"Giovannoni","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2025.106866_bib0018","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s12325-022-02164-8","article-title":"Health-related quality of life with diroximel fumarate in patients with relapsing forms of multiple sclerosis: findings from qualitative research using patient interviews","volume":"39","author":"Gudesblatt","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2025.106866_bib0019","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2147\/TCRM.S174864","article-title":"A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients","author":"Gugliandolo","year":"2018","journal-title":"Ther. Clin. Risk. Manage"},{"key":"10.1016\/j.msard.2025.106866_bib0020","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s13311-017-0566-3","article-title":"Economics and cost-effectiveness of multiple sclerosis therapies in the USA","volume":"14","author":"Hartung","year":"2017","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.msard.2025.106866_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.647811","article-title":"Treatment switching and discontinuation over 20 years in the big multiple sclerosis data network","volume":"12","author":"Hillert","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106866_bib0022","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106866_bib0023","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40263-017-0444-x","article-title":"Health-related quality of life in patients with multiple sclerosis: impact of disease-modifying drugs","volume":"31","author":"Jongen","year":"2017","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.msard.2025.106866_bib0024","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106866_bib0025","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5152\/npa.2015.8825","article-title":"Evaluation of the adherence to immunmodulatory treatment in patients with multiple sclerosis","volume":"52","author":"K\u00f6\u015fkderelio\u011flu","year":"2015","journal-title":"Noro Psikiyatr. Ars."},{"key":"10.1016\/j.msard.2025.106866_bib0026","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jval.2019.10.011","article-title":"Disease-modifying therapy adherence and associated factors in a national sample of Medicare patients with multiple sclerosis","volume":"23","author":"Li","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2025.106866_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102826","article-title":"Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"20","author":"Liu","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2025.106866_bib0028","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/1352458516657440","article-title":"Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective study","volume":"23","author":"McKay","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106866_bib0030","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200005","article-title":"Disease-modifying drugs for multiple sclerosis and association with survival","volume":"9","author":"Ng","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106866_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-020-01830-0","article-title":"Real-world adherence to, and persistence with, once-and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"20","author":"Nicholas","year":"2020","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2025.106866_bib0032","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1517\/17425247.2016.1158161","article-title":"Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study","volume":"13","author":"Paolicelli","year":"2016","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.msard.2025.106866_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102124","article-title":"Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)","volume":"42","author":"Patti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106866_bib0034","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.3390\/nu16244368","article-title":"Mechanisms and potential benefits of neuroprotective agents in neurological health","volume":"16","author":"Pekdemir","year":"2024","journal-title":"Nutrients."},{"key":"10.1016\/j.msard.2025.106866_bib0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78212-6","article-title":"Prediction of disease progression and outcomes in multiple sclerosis with machine learning","volume":"10","author":"Pinto","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106866_bib0036","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.20197","article-title":"Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study","volume":"56","author":"Pittock","year":"2004","journal-title":"Ann. Neurol.: Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"key":"10.1016\/j.msard.2025.106866_bib0037","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/135245850100700512","article-title":"Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review","volume":"7","author":"Ramsaransing","year":"2001","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106866_bib0038","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ensci.2017.05.002","article-title":"Definition, prevalence and predictive factors of benign multiple sclerosis","volume":"7","author":"Reynders","year":"2017","journal-title":"eNeurologicalSci."},{"key":"10.1016\/j.msard.2025.106866_bib0039","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1185\/03007990903554257","article-title":"Persistence and adherence to disease modifying drugs among patients with multiple sclerosis","volume":"26","author":"Reynolds","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2025.106866_bib0040","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-1331.2011.03648.x","article-title":"Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response","volume":"19","author":"R\u00edo","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106866_bib0041","series-title":"Adherence to long-term therapies: evidence for action","author":"Sabat\u00e9","year":"2003"},{"key":"10.1016\/j.msard.2025.106866_bib0042","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1177\/1352458518790390","article-title":"Determinants of therapy switch in multiple sclerosis treatment-na\u00efve patients: a real-life study","volume":"25","author":"Sacc\u00e0","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106866_bib0043","first-page":"15","article-title":"Economic sanctions against Iran as an important factor in threatening the health of patients with multiple sclerosis","volume":"20","author":"Sahraian","year":"2021","journal-title":"Curr J Neurol"},{"key":"10.1016\/j.msard.2025.106866_bib0044","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106866_bib0045","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106866_bib0046","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/GCO.0000000000000731","article-title":"Pregnancy and multiple sclerosis: an update","volume":"33","author":"Varyt\u0117","year":"2021","journal-title":"Curr Opin Obs. Gynecol"},{"key":"10.1016\/j.msard.2025.106866_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101929","article-title":"Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review","volume":"39","author":"Visser","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106866_bib0048","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106866_bib0049","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","article-title":"Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review","volume":"269","author":"Washington","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106866_bib0050","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211039648","article-title":"Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"14","author":"Wiendl","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500608X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500608X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:05:00Z","timestamp":1785755100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500608X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"alternative-id":["S221103482500608X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106866","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of change in disease-modifying drugs in patients with multiple sclerosis: A registry-based study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106866"}}